Physician profile

Danielle O'Hara

Chapel Hill, NC

NPI 1871114264

$2,203.63

in general payments reported to CMS, 2019-2025

3 companies · $2,204 in 2025

The $2,204 reported for 2025 was more than what 94% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$1,538.53
Food and Beverage$411.78
Education$253.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Edwards Lifesciences Corporation $1,905.39 2025 Inspiris Resilia Aortic Valve, Konect Resilia, Mitris Resilia Mitral Valve
Abbott Laboratories $253.32 2025 Ensite
Tricoast Surgical Solutions LLC $44.92 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Danielle O'Hara

$2,203.63

in general payments reported 2019-2025

Years
2025
Top company
Edwards Lifesciences Corporation
Context
The $2,204 reported for 2025 was more than what 94% of providers received nationally.

https://glasscript.com/doctor/11958680/danielle-o-hara

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.